Lets talk about this ASX ANNOUNCEMENT ADMEDUS TO SHOWCASE...

Lets talk about this
ASX ANNOUNCEMENT
ADMEDUS
TO SHOWCASE
CARDIOCEL
®
AT
EUROPEAN ASSOCIATION
FOR CARDIO
-
THORACIC SURGERY (EACTS) ANNUAL MEETING

Key Sponsor
of
Techno
-
College, 11
th
October
, 2014

Exhibiting at b
ooth #123,
12th
-
14
th
October
, 2014

Admedus hosting
CardioCel
®
Satellite Symposium, 13
th
October
,
2014
Brisbane, Australia
,
10
th
October
,
2014
Admedus L
imi
t
e
d
(ASX:AHZ)
announced
today
its attendance at the European
Association for Cardio
-
Thoracic Surgery (EACTS)
28
th
Annual Meeting to be held in
Milan
from the
11
th
-
15
th
October
,
2014.
Admedus will be showcasing CardioCel
®
,
its advanced cardiovascular scaffold
currently
marketed in Europe and the US
, at its booth and at a number of presentations and
symposia
.
Following CE marking and FDA 510k clearance,
CardioCel
®
is seeing
increasing adoption as the
tissue
of choice for the repair of congenital heart
deformities, more complex heart
defects and heart valve repair procedures
.
CardioCel
®
c
linical data
will feature
on Saturday,
11
th
October at the Admedus
sponsored Techno
-
College, where Admedus will
also have an exhibition booth.
The
Annual Techno
-
College is an integral part of EACTS and provides an update on the
latest developments in the field of cardiovascular, thoracic and congenital surgery.
Admedus will be exhibiting at booth #123 in the main hall from Sunday evening until
Tuesday evening. A
wet lab
will be
set up in
the
booth for hands
-
on CardioCel
®
product demonstrations
.
The CardioCel
®
Satellite Symposium will take place from 12:45
–
14:00 on Monday
,
1
3
th
October at the Milano Congressi in room Amber 6. Chaired by Prof.
Mark
Hazekamp, LUMC, The Netherlands,
the symposium will comprise surgeon
presentations and an open forum on the CardioCel
®
scaffold
t
issue
e
ngineering
p
rocess and clinical usage to date.
Panellists
include:

Prof.
William Neethling, University of Western Australia;

Prof. Tom Karl, Mater
Children’s Hospital, Brisbane;

Mr Olivier Ghez, Royal Brompton Hospital, London
; and

Assoc.
Prof. Geoffrey Strange, Admedus